Evidence map›Paper›PMID 31496690›Full record

ArticleInternational journal of nanomedicine2019

Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative.

Rudra Pangeni, Saurav Kumar Jha, Ruby Maharjan, Jeong Uk Choi, Kwan-Young Chang, Young Kweon Choi, Youngro Byun, Jin Woo Park

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Bile acid transporter-mediated oral drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rudra Pangeni *Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea.
Saurav Kumar Jha *Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea.
Ruby MaharjanResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Jeong Uk ChoiResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Kwan-Young ChangGlobal R&D Center, Icure BNP, Seoul 06170, Republic of Korea.
Young Kweon ChoiGlobal R&D Center, Icure BNP, Seoul 06170, Republic of Korea.
Youngro ByunDepartment of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Jin Woo ParkDepartment of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea.
Mokpo National University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe rational combination of immunotherapy with standard chemotherapy shows synergistic clinical activities in cancer treatment. In the present study, an oral powder formulation of pemetrexed (PMX) was developed to enhance intestinal membrane permeability and investigate its application in metronomic chemotherapy in combination with immunotherapy.

methodsPMX was ionically complexed with a bile acid derivative (N

resultsThe apparent permeability (P

conclusionThese findings indicated the therapeutic potential of a combination of low-dose oral chemotherapy and immunotherapy for synergistic anticancer efficacy.

Indexed as

Drug CompoundingAdministration, OralAnimalsAntineoplastic AgentsBiological AvailabilityBiological TransportCaco-2 CellsCell ProliferationChenodeoxycholic AcidDeoxycholic AcidHumansIntestinesIonsLysineMice, Inbred BALB CPemetrexedAntineoplastic AgentsChenodeoxycholic AcidDeoxycholic Aciddeoxycholyl-L-lysyl-methylesterIonsLysinePemetrexedbile acid derivativeintestinal membrane permeabilityoral deliveryoral metronomic chemotherapyoral powder formulationpemetrexed

Identifiers

PMID31496690
PMCPMC6690926
OpenAlexW2964588567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.